<p>Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data</p>

Abstract

Recent advances in the understanding of the pathophysiology of ulcerative colitis (UC) have led to the expansion of our therapeutic arsenal. Conventional treatment options, including aminosalicylates, corticosteroids, thiopurines, and calcineurin inhibitors, fail to control the disease in a significant proportion of patients. Approximately 25–50% of the patients treated with tumor necrosis factor antibodies (anti-TNFα) are primary and secondary non-responders to therapy. Tofacitinib is a novel orally administered small synthetic molecule that inhibits a homologous family of enzymes, termed Janus kinases that modulate multiple key cytokines involved in the pathogenesis of UC. Phase II and III trials showed promising results in UC, leading the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to approve its administration for the induction and maintenance of remission in moderate-to-severe UC. Herein, we review tofacitinib for the management of UC, its mechanism of action pharmacokinetic properties, efficacy, and safety.

Puerarin Ameliorates 5-Fluorouracil–Induced Intestinal Mucositis in Mice by Inhibiting JAKs

“…Both in vivo and in vitro, puerarin significantly alleviated inflammatory responses and restored the intestinal barrier functions in the intestinal mucositis models by inhibiting the activation of JAK. Oxidative stress can also induce the activation of JAK signaling pathway (Charras et al, 2019;Varyani et al, 2019;Chakrabarti and Visweswariah, 2020), however, antioxidants like N-acetyl-L-cysteine does not significantly inhibit JAK activation compared with JAK inhibitor (Zhou et al, 2017). Overall, these results suggest that puerarin suppressed JAK to exert a protective role against the intestinal mucositis induced by 5-FU.…”

Tofacitinib as an Adjunct Immunomodulator for Treatment of a Patient with Severe COVID-19: A Case Report

“…Infection requiring parenteral antibiotics and hospitalization were rarely observed. 8 In a single center retrospective observational study, addition of Tofacitinib to dexamethasone was associated with improved survival. Patients who were hypoxemic and with increased markers of inflammation, with CRP more than 50 mg/L or ferritin more than 500 ng/ml were administered Tofacitinib.…”

Tofacitinib: una revisión de su uso en pacientes con colitis ulcerosa

“…La seguridad del tofacitinib en niños, mujeres embarazadas y pacientes de edad avanzada no se ha estudiado directamente en la CU. Sin embargo, existe evidencia limitada obtenida del uso de tofacitinib en estas poblaciones especiales para el tratamiento de otras enfermedades diferentes de la CU 49 .…”